Skip to main content

Drug Interactions between Nubeqa and piflufolastat F 18

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

darolutamide piflufolastat F-18

Applies to: Nubeqa (darolutamide) and piflufolastat F 18

MONITOR: Imaging results with flotufolastat or piflufolastat may be affected by coadministration of androgen deprivation therapy (ADT) or other therapies targeting the androgen pathway. Flotufolastat and piflufolastat are prostate specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agents that visualize the presence of PSMA in tissues. PSMA is usually overexpressed in malignant prostate cancer cells. Cellular PSMA expression is regulated by the androgen receptor, and therefore drugs that affect the androgen pathway may also affect PSMA expression. However, the impact on imaging results from concomitant use of these therapies with flotufolastat or piflufolastat has not been established.

MANAGEMENT: Caution is recommended when interpreting flotufolastat or piflufolastat PSMA-targeted PET results in men receiving ADT or other therapies targeting the androgen pathway. Clinical correlation, such as histopathological evaluation of the suspected prostate cancer site may be needed if an imaging error is suspected.

References (2)
  1. (2022) "Product Information. Pylarify (piflufolastat F-18)." Progenics Pharmaceuticals, Inc.
  2. (2023) "Product Information. Posluma (flotufolastat F-18)." Blue Earth Diagnostics Inc.

Drug and food interactions

Moderate

darolutamide food

Applies to: Nubeqa (darolutamide)

ADJUST DOSING INTERVAL: Food enhances the oral absorption of darolutamide. According to the prescribing information, bioavailability of darolutamide increased by 2.0 to 2.5-fold when administered with food. A similar increase in exposure was observed for the active metabolite keto-darolutamide.

MANAGEMENT: Darolutamide should be administered with food.

References (1)
  1. (2019) "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer